- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03413956
An Observational Study to Explore Clinical Characteristics of the Patients With T1 Non-small Cell Lung Cancer
May 18, 2018 updated by: Feng Jiang, Jiangsu Cancer Institute & Hospital
A Multi-centre Real-world Non-interventional Observational Study to Explore Clinical Characteristics of the Chinese Patients With T1 Non-small Cell Lung Cancer Complicated With Lymph Metastases
The real-world observational study was designed to explore the odd factors of lymph metastases in the patients with T1 non-small cell lung cancer, the effects of clinical characteristics on lymph metastases, and compare the differences in lymph metastases in the subgroups.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The trial is a multi-centre, real-world non-interventional observational study.
In the study, the patients with T1 non-small cell lung cancer enrolled in clinics from 2015 to 2017 were included via a retrospectively review method and the study data on patient demographic/tumor biological characteristics, and clinical treatments were collected to explore the clinical odd factors of lymph metastases, evaluate the effects of clinical characteristics on lymph metastases, and compare the differences in lymph metastases in the subgroups.
Study Type
Observational
Enrollment (Actual)
10885
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100029
- China-Japan Friendship Hospital
-
Beijing, Beijing, China, 100853
- China People's Liberation Army Hospital
-
-
Henan
-
Zhengzhou, Henan, China
- Henan Cancer Hospital
-
Zhengzhou, Henan, China, 450003
- Henan Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Tongji Hospital Affiliated to Tongji Medical College, Huaxi Technology University
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210009
- Jiangsu Cancer Institute and Hospital
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710000
- Xi'an Tangdu Hospital
-
-
Shanghai
-
Shanghai, Shanghai, China, 200030
- Shanghai Chest Hospital
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- West China Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310006
- First Hospital Affiliated to Medical College, Zhejiang University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
The eligible subjects are the Chinese T1 patients with non-small cell lung cancer complicated with lymph metastases
Description
Inclusion Criteria:
- Patients who received surgeries from 2015 to 2017;
- Pathologically diagnosed patients with T1 non-small cell lung cancer;
Exclusion Criteria:
- Patients with tumor treatments (including chemotherapies, radiotherapies, biological therapies, intervention therapies)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
NSCLC patients with lymph metastases
Pathologically diagnosed patients with T1 non-small cell lung cancer complicated with lymph metastases after surgeries
|
Surgeries
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of the patients with lymph metastases
Time Frame: 2015 - 2017
|
Percentages of the patients with lymph metastases categorised by patient demographic and tumor biological characteristics
|
2015 - 2017
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentages of N0/N1/N2/N3 patients
Time Frame: 2015 - 2017
|
Percentages of N0/N1/N2/N3 patients in the target population
|
2015 - 2017
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of N2 patients with lymph nodes
Time Frame: 2015 - 2017
|
Percentages of N2 patients with lymph nodes in N2 population
|
2015 - 2017
|
|
Percentage of patients with lymph metastases categorised by tumor baseline characteristics
Time Frame: 2015 - 2017
|
Percentage of patients with lymph metastases categorised by tumor baseline characteristics
|
2015 - 2017
|
|
Number of lymph nodes in N2 patients
Time Frame: 2015 - 2017
|
Number of lymph nodes in N2 patients categorised by tumor baseline characteristics
|
2015 - 2017
|
|
Percentage of patients with N2 skip metastases
Time Frame: 2015 - 2017
|
Percentage of patients with N2 skip metastases categorised by tumor baseline characteristics
|
2015 - 2017
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Lin Xu, Jiangsu Cancer Institute and Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2017
Primary Completion (Actual)
March 30, 2018
Study Completion (Actual)
March 30, 2018
Study Registration Dates
First Submitted
January 15, 2018
First Submitted That Met QC Criteria
January 22, 2018
First Posted (Actual)
January 29, 2018
Study Record Updates
Last Update Posted (Actual)
May 21, 2018
Last Update Submitted That Met QC Criteria
May 18, 2018
Last Verified
May 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JS-LC-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Small Cell Lung Cancer
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
Royal Marsden NHS Foundation TrustUniversity of Cambridge; Royal Brompton & Harefield NHS Foundation Trust; Institute... and other collaboratorsRecruitingNon Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Locally Advanced NSCLC - Non-Small Cell Lung Cancer | Oncogene-addicted Non Small Cell Lung Cancer | Early-stage Operable Non Small Cell Lung Cancer | Stage 2/3 Operable Non Small Cell Lung CancerUnited Kingdom
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
Jiangxi Provincial People's HopitalNot yet recruitingNon-Small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV | Non-small Cell Lung Cancer RecurrentChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
University of California, DavisNational Cancer Institute (NCI)RecruitingNon Small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IV | Non-small Cell Lung Cancer Stage IIIC | Non-small Cell Lung Cancer UnresectableUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
Clinical Trials on Surgeries
-
The First Affiliated Hospital of Guangzhou Medical...CompletedNSCLC, Stage III | NSCLC, Stage I | NSCLC, Stage IIChina
-
The First Affiliated Hospital of Guangzhou Medical...UnknownNon-small Cell Lung CancerChina
-
Henan Cancer HospitalLinkDoc Technology (Beijing) Co. Ltd.Unknown
-
Chinese PLA General HospitalLinkDoc Technology (Beijing) Co. Ltd.Completed
-
China-Japan Friendship HospitalLinkDoc Technology (Beijing) Co. Ltd.CompletedNon-small Cell Lung CancerChina
-
Tang-Du HospitalLinkDoc Technology (Beijing) Co. Ltd.UnknownNon Small Cell Lung CancerChina
-
Assiut UniversityNot yet recruiting
-
Assiut UniversityNot yet recruiting
-
Maharishi Markendeswar University (Deemed to be...Not yet recruitingNeonatal Disorder